Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
Opravil
Milos
M
Baumann
Doris
D
Chave
Jean-Philippe
JP
Furrer
Hansjakob
H
Calmy
Alexandra
A
Bernasconi
Enos
E
Blasko
Monika
M
Vernazza
Pietro
P
Ledergerber
Bruno
B
Perrin
Luc
L
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015224:Dideoxynucleosides / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure; D015215:Zidovudine / Q000008:administration & dosage; D000099227:Abacavir
D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D000099227:Abacavir